Michael J. Fox Foundation
The letter encourages drug developers to "further study and use" αSyn-SAA testing for selecting patients for clinical trials for Parkinson's and related diseases.
The company recently published a study in JAMA on the test and is in the middle of two additional clinical trials as it closes a $6 million Series A funding round.
Octave Bioscience Wins $10M Grant From Michael J. Fox Foundation
The firm will use the funds to develop a protein panel that can help assess disease activity and progression in individuals with Parkinson's.
The assay could allow clinicians to diagnose synucleinopathies like Parkinson's disease without requiring a lumbar puncture to collect cerebrospinal fluid.
NIH Launches Parkinson's Disease Research Partnership
The partnership includes biopharmaceutical, life science, and non-profit organizations, as well as several US government agencies.